MEDS RSI Chart
Last 7 days
-16.4%
Last 30 days
424.4%
Last 90 days
387.3%
Trailing 12 Months
6586.1%
Historical Charts for Stock Metrics
Year | Q1 | Q2 | Q3 | Q4 |
---|---|---|---|---|
2023 | 10.5M | 9.4M | 0 | 0 |
2022 | 10.1M | 11.5M | 11.3M | 11.4M |
2021 | 18.0M | 13.3M | 9.5M | 9.9M |
2020 | 8.1M | 12.8M | 16.8M | 17.1M |
2019 | 4.5M | 5.6M | 7.0M | 7.4M |
2018 | 3.1M | 3.2M | 3.3M | 3.8M |
2017 | 2.8M | 2.9M | 3.0M | 3.0M |
2016 | 2.4M | 2.7M | 3.0M | 3.2M |
2015 | 1.9M | 2.8M | 4.1M | 2.1M |
2014 | 1.1M | 1.2M | 1.4M | 1.5M |
2013 | 0 | 0 | 0 | 955.9K |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
Jan 05, 2024 | patel prashant | acquired | - | - | 150,000 | interim cfo and director |
Jan 05, 2024 | ajjarapu surendra k | acquired | - | - | 150,000 | chairman and ceo |
Jan 16, 2023 | peterson michael l | acquired | - | - | 100,000 | - |
Dec 30, 2022 | newell a. jeffrey | acquired | - | - | 237,186 | - |
Dec 13, 2022 | huffman janet | acquired | - | - | 50,000 | cfo, pao, pfo |
Sep 01, 2022 | pope charles l | acquired | - | - | 54,525 | - |
Sep 01, 2022 | ajjarapu surendra k | acquired | - | - | 51,724 | ceo |
Sep 01, 2022 | patel prashant | acquired | - | - | 8,620 | president and coo |
Sep 01, 2022 | fell donald g. | acquired | - | - | 54,525 | - |
Sep 01, 2022 | huffman janet | acquired | - | - | 21,551 | cfo, pao, pfo |
Which funds bought or sold MEDS recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
Feb 14, 2024 | Royal Bank of Canada | unchanged | - | - | - | -% |
Feb 14, 2024 | BANK OF AMERICA CORP /DE/ | unchanged | - | -27.00 | 78.00 | -% |
Feb 13, 2024 | Tower Research Capital LLC (TRC) | added | 92.57 | 3,243 | 10,906 | -% |
Feb 13, 2024 | Qube Research & Technologies Ltd | reduced | -50.00 | -886 | 520 | -% |
Feb 09, 2024 | WELLS FARGO & COMPANY/MN | added | 166 | 21.00 | 42.00 | -% |
Feb 07, 2024 | CONCOURSE FINANCIAL GROUP SECURITIES, INC. | sold off | - | - | - | -% |
Jan 18, 2024 | Blue Trust, Inc. | unchanged | - | -2,000 | 3,000 | -% |
Unveiling Trxade Group Inc's Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Peers (Alternatives to Trxade Group Inc)
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
JNJ | 380.6B | 85.2B | 10.83 | 4.47 | ||||
MRK | 333.8B | 60.1B | 914.53 | 5.55 | ||||
PFE | 156.9B | 46.5B | -113.02 | 3.37 | ||||
AMGN | 153.4B | 28.2B | 22.84 | 5.44 | ||||
GILD | 91.0B | 27.1B | 16.06 | 3.35 | ||||
TEVA | 16.2B | 15.8B | -28.08 | 1.02 | ||||
MID-CAP | ||||||||
ALKS | 4.6B | 1.7B | 12.8 | 2.74 | ||||
PRGO | 4.3B | 4.7B | -335.7 | 0.92 | ||||
BHC | 3.8B | 8.8B | -6.47 | 0.44 | ||||
AMPH | 2.1B | 644.4M | 15.22 | 3.25 | ||||
SMALL-CAP | ||||||||
TLRY | 1.8B | 700.5M | -1.29 | 2.63 | ||||
TXMD | 24.2M | 70.0M | 0.35 | 0.34 | ||||
ACRX | 18.7M | - | -1.01 | 0.22 | ||||
ACOR | 14.8M | 111.1M | -0.93 | 0.13 | ||||
AGRX | 929.3K | 20.0M | -0.07 | 0.05 |
Trxade Group Inc News
Income Statement (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 |
Revenue | -100.0% | - | 2,251 | 2,248 | 2,529 | 2,400 | 3,279 | 3,240 | 2,388 | 2,550 | 1,898 | 3,053 | 1,994 | 6,332 | 6,593 | 2,203 | 1,696 | 2,311 | 1,916 | 1,513 | 1,294 | 847 |
Cost Of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 2.00 |
Gross Profit | 3.6% | 1,705 | 1,645 | 1,557 | 1,510 | 1,372 | 1,171 | 1,336 | 1,240 | 1,281 | 841 | 1,383 | 133 | 1,929 | 2,005 | 1,640 | 1,250 | 1,311 | 1,163 | 1,147 | 847 | 845 |
Operating Expenses | 28.1% | 2,550 | 1,990 | 1,904 | 3,863 | 1,591 | 2,274 | 2,304 | 2,023 | 2,577 | 3,411 | 2,028 | - | - | - | - | - | - | - | - | - | - |
S&GA Expenses | 101.3% | 614 | 305 | 377 | 345 | 230 | 547 | 651 | -116 | 917 | 648 | 448 | 1,713 | 1,783 | 2,540 | 1,452 | 1,239 | 1,133 | 1,031 | 975 | 1,157 | 753 |
Interest Expenses | 39.3% | 252 | 181 | 62.00 | 196 | 130 | 9.00 | 1.00 | 2.00 | 6.00 | 9.00 | 7.00 | 7.00 | 7.00 | 7.00 | 8.00 | 6.00 | 13.00 | 16.00 | 18.00 | 18.00 | 13.00 |
Income Taxes | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Net Income | -78.5% | -3,525 | -1,974 | -677 | -908 | -503 | -1,112 | -965 | -784 | -1,301 | -2,578 | -651 | -2,312 | 138 | -542 | 180 | -495 | 28.00 | 58.00 | 125 | -187 | 94.00 |
Net Income Margin | -74.4% | -0.75* | -0.43* | -0.31* | -0.30* | -0.30* | -0.36* | -0.56* | -0.54* | -0.72* | -0.41* | -0.19* | -0.15* | -0.04* | - | - | - | - | - | - | - | - |
Free Cashflow | -291.7% | -603 | 315 | -945 | 1,216 | -590 | -1,192 | -1,014 | -440 | -752 | -705 | -724 | -729 | 2,483 | - | - | - | - | - | - | - | - |
Balance Sheet | ||||||||||||||||||||||
Description | (%) Q/Q | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 |
Assets | 478.2% | 21,654 | 3,745 | 4,038 | 3,710 | 4,480 | 5,672 | 5,840 | 5,766 | 5,514 | 6,896 | 9,693 | 9,793 | 11,854 | 11,732 | 11,474 | 5,571 | 5,855 | 5,855 | 3,299 | 2,228 | 306 |
Current Assets | 164.8% | 5,548 | 2,095 | 2,386 | 2,093 | 2,373 | 3,347 | 3,597 | 4,374 | 5,189 | 6,536 | 9,155 | 9,221 | 10,643 | 10,123 | 9,795 | 3,803 | 4,315 | 1,952 | 1,491 | 1,466 | 306 |
Cash Equivalents | -95.4% | 34.00 | 746 | 1,200 | 1,095 | 322 | 962 | 1,871 | 3,123 | 3,572 | 4,520 | 5,209 | 5,920 | 6,648 | 4,151 | 7,701 | 2,872 | 3,359 | 540 | 534 | 870 | 127 |
Inventory | 1777.1% | 3,027 | 161 | 126 | 68.00 | 76.00 | 127 | 274 | 56.00 | 95.00 | 139 | 470 | 1,258 | 1,647 | 1,819 | 368 | 57.00 | 63.00 | 547 | 62.00 | 80.00 | 100 |
Net PPE | 383.3% | 288 | 60.00 | 62.00 | 65.00 | 68.00 | 71.00 | 74.00 | 99.00 | 13.00 | 15.00 | 161 | 162 | 150 | 151 | 197 | 175 | 11.00 | 13.00 | 14.00 | 15.00 | - |
Goodwill | - | 5,129 | - | - | - | - | - | - | - | - | - | - | - | 726 | 726 | 726 | 726 | 726 | 726 | 726 | 726 | 726 |
Liabilities | 100.3% | 10,094 | 5,040 | 3,383 | 3,367 | 3,333 | 3,868 | 2,953 | 1,996 | 897 | 1,109 | 1,492 | 1,114 | 1,027 | 1,581 | 1,837 | 1,431 | 1,964 | 2,338 | 2,081 | 1,383 | 239 |
Current Liabilities | 113.3% | 9,092 | 4,263 | 2,550 | 2,147 | 2,061 | 2,546 | 1,596 | 926 | 655 | 861 | 1,238 | 842 | 535 | 720 | 951 | 521 | 956 | 1,085 | 808 | 860 | 239 |
Shareholder's Equity | 993.0% | 11,560 | -1,294 | 655 | 763 | 1,357 | 1,805 | 2,888 | 3,770 | 4,617 | 5,787 | 8,202 | 8,679 | 10,827 | 10,151 | 9,637 | 4,140 | 3,891 | 1,340 | 1,218 | 845 | 326 |
Retained Earnings | 1.7% | -21,529 | -21,900 | -19,900 | -19,719 | -18,800 | -18,300 | -17,213 | -16,247 | -15,463 | -14,161 | -11,583 | -10,931 | -8,619 | -8,757 | -8,215 | -8,395 | -7,900 | -7,927 | -7,985 | -8,111 | 7.00 |
Additional Paid-In Capital | 60.7% | 33,090 | 20,586 | 20,560 | 20,483 | 20,193 | 20,112 | 20,083 | 20,018 | 20,080 | 19,948 | 19,785 | 19,611 | 19,446 | 18,909 | 17,852 | 12,536 | 11,790 | 9,268 | 9,204 | 8,956 | - |
Shares Outstanding | 20.0% | 819 | 683 | 681 | 626 | 547 | 545 | 545 | 544 | 542 | 541 | 540 | 540 | 505 | - | - | - | - | - | - | - | - |
Minority Interest | - | - | - | - | -420 | -42.43 | -16.69 | 18.00 | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Float | - | - | - | - | - | - | 16,922 | - | - | - | 16,922 | - | - | - | 21,541 | - | - | - | 2,653 | - | - | - |
Cashflow (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 |
Cashflow From Operations | -283.6% | -603 | 329 | -931 | 1,230 | -576 | -1,178 | -1,000 | -426 | -738 | -691 | -710 | -715 | 2,483 | -3,571 | -410 | -182 | 404 | 46.00 | -125 | 42.00 | 85.00 |
Cashflow From Investing | -299.8% | -207 | -51.80 | 333 | -114 | -55.73 | -280 | 23.00 | - | - | - | - | -14.00 | - | - | -23.50 | -82.25 | - | -40.00 | -210 | - | - |
Cashflow From Financing | 115.9% | 115 | -725 | 681 | -303 | -7.86 | 550 | -274 | - | -210 | - | - | 1.00 | 13.00 | 22.00 | 5,264 | -222 | 2,415 | - | 166* | 500 | 300 |
Consolidated Statements of Operations (Unaudited) - USD ($) | 3 Months Ended | 9 Months Ended | ||
---|---|---|---|---|
Sep. 30, 2023 | Sep. 30, 2022 | Sep. 30, 2023 | Sep. 30, 2022 | |
Income Statement [Abstract] | ||||
Revenues | $ 2,058,028 | $ 2,055,803 | $ 5,919,786 | $ 7,993,805 |
Cost of sales | 353,450 | 683,375 | 1,072,934 | 3,991,234 |
Gross profit | 1,704,578 | 1,372,428 | 4,846,852 | 4,002,571 |
Operating expenses: | ||||
Wage and salary expense | 698,030 | 849,371 | 2,077,362 | 2,949,386 |
Professional fees | 418,294 | 82,710 | 782,286 | 256,807 |
Accounting and legal expense | 408,957 | 191,007 | 782,495 | 567,086 |
Technology expense | 410,612 | 238,577 | 1,010,374 | 690,875 |
General and administrative expense | 613,834 | 229,526 | 1,264,902 | 1,392,130 |
Total operating expenses | 2,549,727 | 1,591,191 | 5,917,419 | 5,856,284 |
Operating loss | (845,149) | (218,763) | (1,070,567) | (1,853,713) |
Nonoperating income (expense) | ||||
Change in fair value of warrant liability | 925,320 | (443,308) | ||
Interest income | 8,396 | 4,198 | 8,396 | |
Gain (loss) on disposal of assets | 2,200 | |||
Interest expense | (251,778) | (130,107) | (494,904) | (140,626) |
Total nonoperating income (expense) | 673,542 | (121,711) | (934,014) | (130,030) |
Net loss from continuing operations | (171,607) | (340,474) | (2,004,581) | (1,983,743) |
Net loss on discontinued operations | (3,353,507) | (188,268) | (4,123,028) | (623,096) |
Net loss | (3,525,114) | (528,742) | (6,127,609) | (2,606,839) |
Net loss attributable to TRxADE Health, Inc. | (3,525,114) | (503,003) | (6,127,609) | (2,546,913) |
Net loss attributable to non-controlling interests | $ (25,739) | $ (59,926) | ||
Net loss per common share from continuing operations | ||||
Basic | $ (0.22) | $ (0.57) | $ (2.83) | $ (3.52) |
Diluted | (0.07) | (0.57) | (0.87) | (3.51) |
Net loss per common share from discontinued operations | ||||
Basic | (4.35) | (0.34) | (5.82) | (1.14) |
Diluted | (1.42) | (0.34) | (1.79) | (1.14) |
Net loss attributable to common stockholders | ||||
Basic | (4.57) | (0.91) | (8.65) | (4.66) |
Diluted | $ (1.49) | $ (0.91) | $ (2.66) | $ (4.64) |
Weighted average common shares outstanding | ||||
Basic | 771,192 | 549,977 | 708,116 | 546,879 |
Diluted | 2,363,233 | 551,724 | 2,300,157 | 548,626 |
Consolidated Balance Sheets (Unaudited) - USD ($) | Sep. 30, 2023 | Dec. 31, 2022 |
---|---|---|
Current Assets | ||
Cash | $ 34,031 | $ 1,094,891 |
Accounts receivable, net | 850,103 | 649,263 |
Inventory | 3,026,918 | 68,448 |
Prepaid assets | 246,093 | 104,462 |
Notes receivable | 1,275,000 | |
Other receivables | 115,684 | |
Current assets of discontinued operations | 176,057 | |
Total Current Assets | 5,547,829 | 2,093,121 |
Property plant and equipment, net | 287,920 | 65,214 |
Deposits | 49,031 | 49,031 |
Intangible assets, net | 9,451,562 | |
Goodwill | 5,129,116 | |
Other assets | ||
Operating lease right-of-use assets | 1,188,385 | 1,051,815 |
Noncurrent assets of discontinued operations | 450,845 | |
Total Assets | 21,653,843 | 3,710,026 |
Current Liabilities | ||
Accounts payable | 1,328,599 | 527,984 |
Accrued liabilities | 386,024 | 271,230 |
Other current liabilities | 412,390 | 67,517 |
Contingent funding liabilities | 452,348 | 108,036 |
Current portion of operating lease liabilities | 251,087 | 196,872 |
Notes payable— related party, current portion | 5,230,000 | |
Warrant liability | 1,031,841 | 588,533 |
Current liabilities of discontinued operations | 219,952 | |
Total Current Liabilities | 9,092,289 | 2,146,791 |
Long Term Liabilities | ||
Operating lease liabilities, net of current portion | 976,869 | 887,035 |
Notes payable- related party, net of current portion | 25,000 | |
Total Liabilities | 10,094,158 | 3,367,159 |
Stockholders’ Equity | ||
Common stock, $0.00001 par value; 6,666,667 shares authorized; 818,961 and 626,247 shares issued and outstanding, as of September 30, 2023 and December 31, 2022, respectively | 8 | 6 |
Additional paid-in capital | 33,089,652 | 20,482,666 |
Retained deficit | (21,529,975) | (19,719,536) |
Total TRxADE Health Inc. Stockholders’ Equity | 11,559,685 | 763,136 |
Non-controlling interest in subsidiary | (420,269) | |
Total Stockholders’ Equity | 11,559,685 | 342,867 |
Total Liabilities and Stockholders’ Equity | 21,653,843 | 3,710,026 |
Series A Preferred Stock [Member] | ||
Stockholders’ Equity | ||
Preferred stock, value | ||
Series B Preferred Stock [Member] | ||
Stockholders’ Equity | ||
Preferred stock, value | ||
Nonrelated Party [Member] | ||
Current Liabilities | ||
Notes payable— related party, current portion | 5,230,000 | |
Long Term Liabilities | ||
Notes payable- related party, net of current portion | 25,000 | |
Related Party [Member] | ||
Current Liabilities | ||
Notes payable— related party, current portion | 166,667 | |
Long Term Liabilities | ||
Notes payable- related party, net of current portion | $ 333,333 |